Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial
Christopher T Ritchlin, Arthur Kavanaugh, Joseph F. Merola, Georg Schett, José U. Scher, Richard B. Warren, Alice B. Gottlieb, Deepak Assudani, Kathy Bedford-Rice, Jason Coarse, Barbara Ink, Iain B. McInnes
Topics & Concepts
MedicinePlaceboPsoriatic arthritisDose-ranging studyClinical endpointInternal medicinePlacebo-controlled studyArthritisRandomized controlled trialRheumatologyGastroenterologyClinical trialSurgeryPhysical therapyDouble blindPathologyAlternative medicinePsoriasis: Treatment and PathogenesisSpondyloarthritis Studies and TreatmentsDermatology and Skin Diseases